Wi-Fi, Smartphones, and Surveillance: The New Face of Schizophrenia Delusions
December 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
Emzeltrectinib, emzeltrectinibum
Class :
Antineoplastic agent/TK (tyrosine kinase) inhibitor
Brand Name :
N/A
Synonyms :
Emzeltrectinib, emzeltrectinibum
Class :
Antineoplastic agent/TK (tyrosine kinase) inhibitor
Dosage Forms & Strengths
This drug is under clinical trial to study its efficacy against different types of cancer.
Dosage Forms & Strengths
Safety and efficacy study is not established
Refer to adult dosing
Actions and spectrum:
Emzeltrectinib acts by potentially inhibiting tyrosine kinase and thus produces an antineoplastic effect.
Frequency not defined
Limited data available
Black Box Warning
No special black box warnings are available for this drug
Contraindication/Caution:
Contraindication:
Limited data available
Pregnancy/Lactation
Pregnancy consideration:
Safety and efficacy studies in pregnant women are not established
Lactation:
Safety and efficacy studies in lactating mothers are not established
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Emzeltrectinib is an antineoplastic drug.
Pharmacodynamics:
Emzeltrectinib inhibits tyrosine kinase potentially.
Pharmacokinetics:
The pharmacokinetic study of emzeltrectinib needs to be documented.
Administration:
Emzeltrectinib is an investigational drug, and it is to be administered as advised by the doctor
Patient information leaflet
Generic Name: emzeltrectinib
Why do we use emzeltrectinib?
Emzeltrectinib is under investigation for its use as an antineoplastic agent. This drug acts by inhibiting tyrosine kinase.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
